Impact of COVID-19 on viral respiratory infection epidemiology in young children: A single-center analysis

David Paul Shen¹, François Vermeulen²,³, Anne Debeer³,⁴, Katrien Lagrou⁵,⁶ and Anne Smits³,⁴,⁷*

Background: The COVID-19 pandemic impacts different health aspects. Concomitant with the adoption of non-pharmaceutical interventions (NPIs) to reduce the spread of SARS-CoV-2, global surveillance studies reported a reduction in occurrence of respiratory pathogens like influenza A and B virus (IAV & IBV) and respiratory syncytial virus (RSV). We hypothesized to observe this collateral benefit on viral respiratory infection epidemiology in young children.

Methods: Respiratory samples of children aged below 6 years, presenting at the outpatient clinic, emergency department, or pediatric infectious diseases department of the University Hospitals Leuven, between April 2017 and April 2021 were retrospectively analyzed. The occurrence (positivity rate), and seasonal patterns of viral respiratory infections were described. Chi-squared or Fisher’s exact test (and Bonferroni correction) were used to explore differences in occurrence between 2020-2021 and previous 12-month (April to April) periods.

Results: We included 3020 samples (453 respiratory panels, 2567 single SARS-CoV-2 PCR tests). IAV and IBV were not detected from March and January 2020, respectively. For IAV, positivity rate in 2020–2021 (0%, n = 0) was significantly different from 2018–2019 (12.4%, n = 17) (p < 0.001) and 2019–2020 (15.4%, n = 19) (p < 0.001). IBV positivity rate in 2020–2021 (0%, n = 0) was not significantly different from previous periods. RSV occurrence was significantly lower in 2020–2021 (3.2%, n = 3), compared to 2017-2018 (15.0%, n = 15) (p = 0.006), 2018–2019 (16.1%, n = 22) (p = 0.002) and 2019-2020 (22.8%, n = 28) (p < 0.001). The RSV (winter) peak was absent and presented later (March–April 2021). Positivity rate of parainfluenza virus 3 (PIV-3) was significantly higher in 2020-2021 (11.8%, n = 11) than 2017-2018 (1%, n = 1) (p = 0.002). PIV-3 was absent from April 2020 to January 2021, whereas no clear seasonal pattern was distinguished the other years. For the other viruses tested, no significant differences in occurrence were observed between 2020-2021 and previous periods. From March 2020 onwards, 20 cases (0.7%) of SARS-CoV-2 were identified.
Conclusion: These findings reinforce the hypothesis of NPIs impacting the epidemiology of influenza viruses and RSV in young children. Compared to previous periods, no IAV and IBV cases were observed in the 2020-2021 study period, and the RSV peak occurred later. Since the pandemic is still ongoing, continuation of epidemiological surveillance, even on a larger scale, is indicated.

KEYWORDS
COVID-19, respiratory infection, epidemiology, children, influenza, RSV, non-pharmaceutical interventions

Introduction

The COVID-19 pandemic has a large impact on different health aspects. Preventative measures such as lockdowns, social distancing, the use of face masks, and increased awareness on hand hygiene have been adopted widely to reduce the spread of the formerly unknown SARS-CoV-2 (1). These non-pharmaceutical interventions (NPIs), also known as public health measures or community mitigation strategies, are believed to be effective against the transmission of other respiratory infections as well (2).

Flu-like symptoms trigger a significant proportion of primary care visits (3). Furthermore, acute respiratory infections are major causes of morbidity and mortality in the youngest and eldest populations (4–9). In the absence of a pandemic, seasonal peaks of influenza A and B virus (IAV & IBV), respiratory syncytial virus (RSV), and common coronaviruses typically occur during the winter season (10, 11). Parainfluenza virus (PIV), human metapneumovirus (hMPV), adenovirus (ADV), rhinovirus (RV), and bocavirus circulate throughout the year, with usually higher infection rates during winter (10, 11). Compared to other age categories, children below six years have a higher incidence and vulnerability for viral respiratory infections (11). Especially RSV carries a significant hospitalization rate (12, 13). In contrast, with COVID-19, children are more often asymptomatic or have a milder disease course (14–16).

Concomitant with the implementation of NPIs to prevent the spread of SARS-CoV-2, the WHO European Region Influenza Surveillance network reported an abrupt end of influenza activity in March 2020, earlier than previous seasons (17). Likewise, the influenza incidence in the United States decreased abruptly within two weeks of the national COVID-19 emergency declaration in March 2020 (18). Also afterwards, global surveillance studies confirmed significantly decreased influenza activity (2, 18–24). Several retrospective studies reported similar findings for other respiratory pathogens, including but not limited to RSV, PIV, and hMPV (24–35).

We hypothesized that the public health measures adopted to reduce the spread of SARS-CoV-2 have a collateral benefit on the occurrence of other respiratory infections. Therefore, the objective of this study was to determine the impact of COVID-19 on the epidemiology of respiratory infections in young children in a single, Belgian university hospital.

Materials and methods

Study population

This retrospective analysis describes the occurrence and seasonal patterns of respiratory infections in young children over a 4-year period (April 16th, 2017, until April 15th, 2021). Inclusion criteria were as follows: children below 6 years of age who presented at the outpatient clinic, the emergency department, or the pediatric infectious diseases department of the University Hospitals Leuven, Belgium, within the predefined period and had at least one respiratory sample collected. Indication for sampling can be respiratory infection (respiratory panel) or SARS-CoV-2 screening (isolated SARS-CoV-2 PCR). The epidemiology and etiology of respiratory infections in this well-defined age category have been described in detail by the scientific community and were therefore selected (11, 13, 31, 36).

Ethical approval has been granted by the Educational-Support Committee of the Research Ethics Committee UZ/KU Leuven and the data was pseudonymized prior to analysis.

Data collection

The retrospective data search was based on a query performed by the Department of Laboratory Medicine of the University Hospitals Leuven, Belgium, in the electronic

Abbreviations: ADV, Adenovirus; COVID-19, Coronavirus disease of 2019; EV, Enterovirus; hMPV, Human metapneumovirus; HRV/ENT, Human rhinovirus/enterovirus; IAV, Influenza A virus; IBV, Influenza B virus; NPIs, Non-pharmaceutical interventions; PIV, Parainfluenza virus; RSV, Respiratory syncytial virus; RV, Rhinovirus; SARS-CoV-2, Severe Acute Respiratory Syndrome coronavirus 2.
laboratory system. The data collected for analysis include age (years), sex (male/female), results of respiratory sampling, types of respiratory sampling (oro- or nasopharyngeal swab, sputum, bronchoalveolar lavage, bronchial or endotracheal aspirate), and date of sampling. Viral \((n = 24)\), bacterial \((n = 6)\), and fungal \((n = 1)\) pathogens were identified using the standard respiratory pathogen panel of the University Hospitals Leuven (37, 38). The test method consists of DNA/RNA-extraction using NucliSens® easyMAG®, followed by real-time polymerase chain reaction (PCR) TaqMan® (37). Because of its poor specificity to differentiate between rhinoviruses (RV) and enteroviruses (EV), the test method was modified to a combined PCR for human rhinovirus/enterovirus (HRV/ENT) in January 2018. For comparability, data of RV and EV before January 2018 were merged. From January 2020 onwards, SARS-CoV-2 was included in the respiratory pathogen panel, and was in addition available as an isolated PCR test. The dataset was provided as a Microsoft® Excel® file. As the focus of current study was analysis of (non-SARS-CoV-2) viral pathogens, data of respiratory panels were selected. For analysis of SARS-CoV-2 occurrence, both results of respiratory panels and isolated SARS-CoV-2 tests were used.

**Statistical methods**

Descriptive statistics were performed. The 4-year study period was divided into four periods of 12 months (e.g., 2017-2018), starting on April 16th and ending on April 15th of the following year. Compared to calendar years (January-December), this allows that the periods each contained a full winter season. The absolute number of positive tests per month or year per identified pathogen was defined as monthly and yearly occurrence respectively. The positivity rate per pathogen (in percent) was calculated by dividing the number of positive tests by the total number of tests performed. For graphical representation, the positivity rate was expressed as a decimal number. The Chi-squared or Fisher’s exact test was used to explore differences in pathogen distribution across the four periods. A \(p\)-value < 0.05 was considered statistically significant.

The Fisher’s exact test was used when at least one of the values in the 2 x 2 contingency table was smaller than five. To correct for multiple testing after comparison of the period 2020-2021 to the previous periods (i.e., 2017-2018, 2018-2019 and 2019-2020), the Bonferroni correction was applied with an adjusted \(p\)-value < 0.01 considered significant. To achieve a general overview on distribution of respiratory pathogens during the study period for the different ages, the number of positive tests of a specific pathogen was divided by the total number of positive tests for each age group and provided as percentage (%). As pathogen distribution by age was not the main objective of the current study, and due to the anticipated limited number of positive tests in some of these subanalyses, no further between-age group and between-period explorations were performed. Statistical analysis was performed using MedCalc® Statistical Software, version 20.015 (MedCalc Software Ltd, Ostend, Belgium), and IBM® SPSS® Statistics for Windows, version 28.0.1.0 (IBM Corp., Armonk, New York, USA).

**Results**

**Study population characteristics**

Out of 3020 respiratory samples (453 respiratory panels and 2567 SARS-CoV-2 PCR tests) in the dataset, the 453 respiratory panels of 411 patients aged 0–5 years were selected for further investigation (Table 1, Figure 1A). Some patients had multiple respiratory samples collected over the years, which were all considered as individual infection episodes. Detection of SARS-CoV-2 was included in the 131 respiratory panels performed since January 2020. Respiratory sampling over four years included 3018 oro- and nasopharyngeal swabs and two bronchoalveolar lavages. Study population characteristics of the respiratory panels are presented in Table 2 and Figure 1B.

The emergency department was the hospital unit with the highest number of respiratory panels performed per year (Supplementary Figure S1A). The age distribution of respiratory panels performed per hospital unit is represented graphically in Supplementary Figure S1B.

Species names of the included pathogens are provided in Table 3.

**Influenza viruses**

No cases of IAV were detected in 2020-2021, which contrasts with previous years: four (4%) positive tests in 2017-2018, 17 (12.4%) in 2018-2019, and 19 (15.4%) in 2019-2020 (Table 3, Supplementary Figure S2). The Fisher’s exact test across all four periods was significant (\(p < 0.001\)). Positivity rate in 2020-2021 was significantly lower than 2018-2019 (\(p < 0.001\)) and 2019-2020 (\(p < 0.001\)). IAV was observed exclusively between December and April, with its last case detected in March 2020 (Figure 2).

As for IBV, four (4%) and two (1.6%) positives were detected from February to March 2018 and from December 2019 to January 2020, respectively (Table 3). The Fisher’s exact test across all four periods was significant (\(p = 0.020\)), although the differences in occurrence between 2020-2021 and the previous periods were non-significant.

**Respiratory syncytial virus**

With only three (3.2%) cases of RSV in 2020-2021, its occurrence decreased compared to 15 (15.0%) positive tests in
TABLE 1  Total number of respiratory samples included in this study.

|                      | 2017–2018 | 2018–2019 | 2019–2020 | 2020–2021 | Total |
|----------------------|-----------|-----------|-----------|-----------|-------|
| Number of respiratory panels | 100       | 137       | 123       | 93        | 453   |
| With SARS-CoV-2 included | 0         | 0         | 38        | 93        | 131   |
| Number of SARS-CoV-2 PCR tests | 0         | 0         | 96        | 2471      | 2567  |
| Total number of respiratory samples | 100       | 137       | 219       | 2564      | 3020  |

The distinction was made based on the analysis performed: a respiratory panel or an (isolated) SARS-CoV-2 PCR test. Detection of SARS-CoV-2 was included in the respiratory panel starting January 2020.

2017–2018, 22 (16.1%) in 2018–2019, and 28 (22.8%) in 2019–2020 (Table 3, Supplementary Figure S3). The Fisher’s exact test across all four periods was significant ($p < 0.001$). Positivity rate of RSV in 2020–2021 was significantly lower than 2017–2018 ($p = 0.006$), 2018–2019 ($p = 0.002$), and 2019–2020 ($p < 0.001$). Remarkably, its characteristic winter peak was absent in 2020–2021, as the positive tests were observed later, i.e., March and April 2021 (Figure 3).

Parainfluenza viruses

Zero (0%) cases of PIV-1 were detected in 2018–2019 and 2020–2021, in contrast with two (2.0%) in 2017–2018 and five (4.1%) in 2019–2020 (Table 3). The Fisher’s exact test across all four periods was significant ($p = 0.021$), while the differences in occurrence between 2020–2021 and previous periods were not. No cases of PIV-2, and PIV-4 were detected in 2020–2021. As the absolute number of positive tests in the previous years was equally low, the difference between 2020–2021 and the previous periods were non-significant (Table 3). However, eleven (11.8%) tests were positive for PIV-3 in 2020–2021, compared to one (1%) in 2017–2018, 13 (9.5%) in 2018–2019, and five (4.1%) in 2019–2020 (Table 3, Supplementary Figure S4). The Fisher’s exact test across all four periods was significant ($p = 0.004$) and the positivity rate of PIV-3 in 2020–2021 was only significantly higher than 2017–2018 ($p = 0.002$, Fisher’s exact). After Bonferroni correction, the difference in occurrence between 2019–2020 and 2020–2021 was considered non-significant ($p = 0.031$, Chi-squared). PIV-3 remained...
| Pathogen                              | 2017–2018 | 2018–2019 | 2019–2020 | 2020–2021 | Total    |
|--------------------------------------|-----------|-----------|-----------|-----------|----------|
| Influenza A virus                    | 4 / 100   | 17 / 137  | 19 / 123  | 0 / 93    | 40 / 453 |
| Positivity rate                      | 4.0%      | 12.4%     | 15.4%     | 0.0%      | 8.8%     |
| Significance level                   | \( p = 0.122 \) | \( p < 0.001^* \) | \( p < 0.001^* \) | \( p < 0.001^* \) | \( p < 0.001^* \) |
| Influenza B virus                    | 4 / 100   | 0 / 137   | 2 / 123   | 0 / 93    | 6 / 453  |
| Positivity rate                      | 4.0%      | 0.0%      | 1.6%      | 0.0%      | 1.3%     |
| Significance level                   | \( p = 0.122 \) | /         | \( p = 0.507 \) | /         | \( p = 0.020^* \) |
| Respiratory syncytial virus          | 15 / 100  | 22 / 137  | 28 / 123  | 3 / 93    | 68 / 453 |
| Positivity rate                      | 15.0%     | 16.1%     | 22.8%     | 3.2%      | 15.0%    |
| Significance level                   | \( p = 0.006^* \) | \( p = 0.002^* \) | \( p < 0.001^* \) | \( p < 0.001^* \) | \( p < 0.001^* \) |
| Parainfluenza virus 1                | 2 / 100   | 0 / 137   | 5 / 123   | 0 / 93    | 7 / 453  |
| Positivity rate                      | 2.0%      | 0.0%      | 4.1%      | 0.0%      | 1.5%     |
| Significance level                   | \( p = 0.498 \) | /         | \( p = 0.072 \) | /         | \( p = 0.021^* \) |
| Parainfluenza virus 2                | 1 / 100   | 1 / 137   | 1 / 123   | 0 / 93    | 3 / 453  |
| Positivity rate                      | 1.0%      | 0.7%      | 0.8%      | 0.0%      | 0.7%     |
| Significance level                   | \( p = 1.000 \) | \( p = 1.000 \) | \( p = 1.000 \) | \( p = 1.000 \) | \( p = 1.000 \) |
| Parainfluenza virus 3                | 1 / 100   | 13 / 137  | 5 / 123   | 11 / 93   | 30 / 453 |
| Positivity rate                      | 1.0%      | 9.5%      | 4.1%      | 11.8%     | 6.6%     |
| Significance level                   | \( p = 0.002^* \) | \( p = 0.570 \) | \( p = 0.031 \) | \( p = 0.004^* \) | \( p = 0.004^* \) |
| Parainfluenza virus 4                | 1 / 100   | 3 / 137   | 2 / 123   | 0 / 93    | 6 / 453  |
| Positivity rate                      | 1.0%      | 2.2%      | 1.6%      | 0.0%      | 1.3%     |
| Significance level                   | \( p = 1.000 \) | \( p = 0.274 \) | \( p = 0.507 \) | \( p = 0.643 \) | \( p = 0.643 \) |
| Adenovirus                           | 26 / 100  | 29 / 137  | 16 / 123  | 15 / 93   | 86 / 453 |
| Positivity rate                      | 26.0%     | 21.2%     | 13.0%     | 16.1%     | 19.0%    |
| Significance level                   | \( p = 0.095 \) | \( p = 0.341 \) | \( p = 0.518 \) | \( p = 0.073 \) | \( p = 0.073 \) |
| Bocavirus                            | 10 / 100  | 13 / 137  | 6 / 123   | 9 / 93    | 38 / 453 |
| Positivity rate                      | 10.0%     | 9.5%      | 4.9%      | 9.7%      | 8.4%     |
| Significance level                   | \( p = 0.940 \) | \( p = 0.962 \) | \( p = 0.171 \) | \( p = 0.444 \) | \( p = 0.444 \) |
| Human metapneumovirus                | 5 / 100   | 9 / 137   | 3 / 123   | 4 / 93    | 21 / 453 |
| Positivity rate                      | 5.0%      | 6.6%      | 2.4%      | 4.3%      | 4.6%     |
| Significance level                   | \( p = 1.000 \) | \( p = 0.569 \) | \( p = 0.467 \) | \( p = 0.461 \) | \( p = 0.461 \) |
| Human rhinovirus/enterovirus †       | 45 / 100  | 56 / 137  | 59 / 123  | 44 / 93   | 213 / 519|
| Positivity rate                      | 45.0%     | 40.9%     | 48.0%     | 47.3%     | 41.0%    |
| Significance level                   | \( p = 0.748 \) | \( p = 0.335 \) | \( p = 0.924 \) | \( p = 0.663 \) | \( p = 0.663 \) |
| Rhinovirus                           | 27 / 66   | /         | /         | /         | 27 / 66  |
| Positivity rate                      | 40.9%     | /         | /         | /         | 40.9%    |
| Significance level                   | /         | /         | /         | /         | /        |
| Enterovirus                          | 13 / 66   | /         | /         | /         | 13 / 66  |
| Positivity rate                      | 19.7%     | /         | /         | /         | 19.7%    |
| Significance level                   | /         | /         | /         | /         | /        |
| Coronavirus 229E                     | 0 / 100   | 2 / 137   | 0 / 123   | 0 / 93    | 2 / 453  |
| Positivity rate                      | 0.0%      | 1.5%      | 0.0%      | 0.0%      | 0.4%     |
| Significance level                   | /         | \( p = 0.516 \) | /         | /         | \( p = 0.345 \) |
| Coronavirus HKU-1                    | 3 / 100   | 3 / 137   | 3 / 123   | 0 / 93    | 9 / 453  |
| Positivity rate                      | 3.0%      | 2.2%      | 2.4%      | 0.0%      | 2.0%     |
| Significance level                   | \( p = 0.247 \) | \( p = 0.274 \) | \( p = 0.261 \) | \( p = 0.453 \) | \( p = 0.453 \) |
| Coronavirus NL63                     | 2 / 100   | 2 / 137   | 2 / 123   | 1 / 93    | 7 / 453  |

(Continued)
TABLE 3 (Continued).

|                        | 2017–2018 | 2018–2019 | 2019–2020 | 2020–2021 | Total |
|------------------------|-----------|-----------|-----------|-----------|-------|
| **Coronavirus OC43**   |           |           |           |           |       |
| Positive tests / total tests | 2 / 100   | 3 / 137   | 2 / 123   | 1 / 93    | 8 / 453 |
| Positivity rate         | 2.0%      | 2.2%      | 1.6%      | 1.1%      | 1.5%  |
| Significance level      | \( p = 1.000 \) | \( p = 0.649 \) | \( p = 1.000 \) | \( p = 1.000 \) | \( p = 0.964 \) |
| **SARS-CoV-2**          |           |           |           |           |       |
| Positive tests / total tests | / /     | 1 / 134   | 19 / 2564 | 20 / 2698 |       |
| Positivity rate         |          | 0.7%      | 0.7%      | 0.7%      |       |
| Significance level      | / /       | \( p = 1.000 \) | \( p = 0.649 \) | \( p = 1.000 \) | \( p = 0.964 \) |
| **Chlamydia pneumoniae**|           |           |           |           |       |
| Positive tests / total tests | 3 / 100   | 1 / 137   | 1 / 123   | 0 / 93    | 5 / 453 |
| Positivity rate         | 3.0%      | 0.7%      | 0.8%      | 0.0%      | 1.1%  |
| Significance level      | \( p = 0.247 \) | \( p = 1.000 \) | \( p = 1.000 \) | \( p = 0.246 \) |       |
| **Chlamydia psittaci**  |           |           |           |           |       |
| Positive tests / total tests | 0 / 100   | 0 / 137   | 0 / 123   | 0 / 93    | 0 / 453 |
| Positivity rate         | 0.0%      | 0.0%      | 0.0%      | 0.0%      | 0.0%  |
| Significance level      | / /       | / /       | / /       | / /       |       |
| **Coxiella burnetii**   |           |           |           |           |       |
| Positive tests / total tests | 0 / 100   | 0 / 137   | 0 / 123   | 0 / 93    | 0 / 453 |
| Positivity rate         | 0.0%      | 0.0%      | 0.0%      | 0.0%      | 0.0%  |
| Significance level      | / /       | / /       | / /       | / /       |       |
| **Cytomegalovirus**     |           |           |           |           |       |
| Positive tests / total tests | 27 / 100  | 40 / 137  | 31 / 123  | 19 / 93   | 117 / 453 |
| Positivity rate         | 27.0%     | 29.2%     | 25.2%     | 20.4%     | 25.8% |
| Significance level      | \( p = 0.286 \) | \( p = 0.136 \) | \( p = 0.411 \) | \( p = 0.511 \) |       |
| **Enterovirus D68**     |           |           |           |           |       |
| Positive tests / total tests | 0 / 34    | 0 / 137   | 2 / 123   | 0 / 93    | 2 / 387 |
| Positivity rate         | 0.0%      | 0.0%      | 1.6%      | 0.0%      | 0.5%  |
| Significance level      | / /       | / /       | / /       | / /       | / /   |
| **Herpes simplex virus 1** | 4 / 100   | 8 / 137   | 6 / 123   | 3 / 93    | 21 / 453 |
| Positivity rate         | 4.0%      | 5.8%      | 4.9%      | 3.2%      | 4.6%  |
| Significance level      | \( p = 1.000 \) | \( p = 0.532 \) | \( p = 0.735 \) | \( p = 0.845 \) |       |
| **Herpes simplex virus 2** | 0 / 100   | 0 / 137   | 0 / 123   | 0 / 93    | 0 / 453 |
| Positivity rate         | 0.0%      | 0.0%      | 0.0%      | 0.0%      | 0.0%  |
| Significance level      | / /       | / /       | / /       | / /       |       |
| **Legionella pneumophila** | 0 / 100   | 0 / 137   | 0 / 123   | 0 / 93    | 0 / 453 |
| Positivity rate         | 0.0%      | 0.0%      | 0.0%      | 0.0%      | 0.0%  |
| Significance level      | / /       | / /       | / /       | / /       |       |
| **MERS-coronavirus**    |           |           |           |           |       |
| Positive tests / total tests | 0 / 100   | 0 / 137   | 0 / 123   | 0 / 93    | 0 / 453 |
| Positivity rate         | 0.0%      | 0.0%      | 0.0%      | 0.0%      | 0.0%  |
| Significance level      | / /       | / /       | / /       | / /       |       |
| **Mycoplama pneumoniae**|           |           |           |           |       |
| Positive tests / total tests | 1 / 100   | 2 / 137   | 5 / 123   | 0 / 93    | 8 / 453 |
| Positivity rate         | 1.0%      | 1.5%      | 4.1%      | 0.0%      | 1.8%  |
| Significance level      | \( p = 1.000 \) | \( p = 0.516 \) | \( p = 0.072 \) | \( p = 0.171 \) |       |
| **Parechovirus**        |           |           |           |           |       |
| Positive tests / total tests | 6 / 100   | 5 / 137   | 4 / 123   | 5 / 93    | 20 / 453 |
| Positivity rate         | 6.0%      | 3.6%      | 3.3%      | 5.4%      | 4.4%  |
| Significance level      | \( p = 0.852 \) | \( p = 0.530 \) | \( p = 0.504 \) | \( p = 0.698 \) |       |
| **Pneumocystis jirovecii** | 8 / 100   | 4 / 137   | 12 / 123  | 7 / 93    | 31 / 453 |
| Positivity rate         | 8.0%      | 2.9%      | 9.8%      | 7.5%      | 6.8%  |
| Significance level      | \( p = 0.903 \) | \( p = 0.125 \) | \( p = 0.568 \) | \( p = 0.122 \) |       |
| **SARS-associated coronavirus** | 0 / 100   | 0 / 137   | 0 / 85    | 0 / 0     | 0 / 322 |
| Positivity rate         | 0.0%      | 0.0%      | 0.0%      | 0.0%      | 0.0%  |

(Continued)
### TABLE 3 (Continued).

|                      | 2017–2018 | 2018–2019 | 2019–2020 | 2020–2021 | Total  |
|----------------------|-----------|-----------|-----------|-----------|--------|
| **Streptococcus pneumoniae** |           |           |           |           |        |
| Positive tests / total tests | 61 / 100  | 84 / 137  | 68 / 123  | 53 / 93   | 266 / 453 |
| Positivity rate       | 61.0%     | 61.3%     | 55.3%     | 57.0%     | 58.7%  |
| Significance level    | p = 0.572 | p = 0.513 | p = 0.803 | p = 0.731 |

Statistical differences in occurrence were explored using the Chi-squared or Fisher’s exact test. The Fisher’s exact test was used when at least one of the values in the 2 x 2 contingency table was smaller than five. Bonferroni correction was applied to compare pathogen occurrence of period 2020-2021 to period 2017-2018, 2018-2019, or 2019-2020 (with significance level provided under each respective column), with an adjusted p-value < 0.01 considered significant (*). For comparison of pathogen occurrence across all four periods (with significance level provided under the column “Total”), a p-value < 0.05 was considered significant (*). Human rhinovirus/enterovirus (†) includes the separate data of rhinovirus and enterovirus until January 2018 as described in Methods.

![Figure 2](https://example.com/figure2.png)

**FIGURE 2**
Monthly occurrence of influenza A virus (IAV) per year: 2017-2018 (A), 2018-2019 (B), 2019–2020 (C), 2020–2021 (D). Monthly occurrence was defined as the number of positive tests per month. Each 12-month period started on April 16th and ended on April 15th of the following year.

absent from April 2020 until January 2021, whereas no clear seasonal pattern could be distinguished during other years. From February 2021 onwards, a rising trend was seen as represented in Figure 4.

### Adenovirus

In 2017-2018, 26 (26%) cases of ADV were detected, compared to 29 (21.2%) in 2018-2019, 16 (13%) in 2019-2020, and 15 (16.1%) in 2020-2021 (Table 3). No significant differences in occurrence of ADV were observed across the four periods. ADV circulated throughout the year during the study period, except for a period of zero positives between May and October 2018.

### Bocavirus

Ten (10.0%) samples tested positive for bocavirus in 2017-2018 (Table 3). Additionally, 13 (9.5%) samples were positive in 2018-2019, and six (4.9%) in 2019-2020. Compared to
nine (9.7%) positives in 2020-2021, the differences in occurrence are non-significant. Except for two cases in February and March 2020, no cases were detected between July 2019 and October 2020.

**Human metapneumovirus**

Regarding hMPV, five (5.0%) cases were detected in 2017-2018, compared to nine (6.6%) in 2018-2019, three (2.4%) in 2019-2020, and four (4.3%) in 2020-2021 (Table 3). The differences in occurrence across the four periods were not significant. Its appearance between December and April was preserved during all four periods.

**Human rhinovirus/enterovirus**

HRV/ENT propagated throughout the year with 54 (32.5%) positive samples in 2017-2018, 56 (40.9%) in 2018-2019, 59 (48.0%) in 2019-2020 and 44 (47.3%) in 2020-2021 (Table 3). The Chi-squared test across the four periods was not statistically significant.

**Common coronaviruses**

During the study period, only two (1.5%) cases of coronavirus 229E were detected in 2018-2019 (Table 3). In contrast to zero positives in 2020-2021, three tests were positive for coronavirus HKU-1 in 2017-2018 (3.0%), 2018-2019 (2.2%), and 2019-2020 (2.4%) (Table 3). Compared to one (1.1%) case in 2020-2021, two cases of coronavirus NL63 were identified in 2017-2018 (2.0%), 2018-2019 (1.5%), and 2019-2020 (1.6%) (Table 3). A single (1.1%) sample tested positive for coronavirus OC43 in 2020-2021, compared to two in 2017-2018 (2.0%) and 2019-2020 (1.6%), and three (2.2%) in 2018-2019 (Table 3). For these common coronaviruses (229E, HKU-1, NL63, OC43), no statistically significant differences in occurrence were observed across the four periods (Table 3).
SARS-CoV-2

With the first case detected in March 2020, 20 (0.7%) tests were positive for SARS-CoV-2 during the investigated study period (Table 3). The highest peak observed consisted of five (2.9%) positives in November 2020 (Supplementary Figure S5).

Other respiratory pathogens

The absolute number of positive tests and positivity rate of other respiratory pathogens included in the respiratory panel are listed in Table 3. None showed a significant difference in occurrence between the 2020-2021 period and the previous periods.

Pathogen distribution by age

The distribution of respiratory pathogens during the study period for the different ages are listed in Supplementary Table S1. The proportion of IAV infections was highest in the age groups of 2 to 5 years old (6.8–8.2% of all positive tests for each age group). A similar pattern was observed for IBV in the age categories of 3 and 4 years old, with 2.1 and 3.4% of all positive tests respectively. With RSV, the ages of 0 (8.6% of all positive tests) and 1 years old (7.3% of all positive tests) were most commonly affected, compared to other age categories. Albeit that the number of positive tests for parainfluenza virus were low, the ages of 1 (4.3% of all positive tests) and 2 (3.7% of all positive tests) had the highest proportions of PIV-3 infections. For further details on the remaining pathogens, we refer to Supplementary Table S1.

Discussion

Respiratory infection epidemiology

This retrospective study investigated the collateral effect of the NPIs adopted to reduce the spread of SARS-CoV-2 on the occurrence of viral respiratory pathogens in young children. As for social restrictions in Belgium, the first lockdown lasted...
from March until beginning of May 2020 (39–42). Except for children of essential workers, schools were closed during this period. Subsequently, from October 2022, new restrictions were gradually implemented (43, 44), until gradual facilitation as of early 2021 (45, 46). See Supplementary Figure S6 for a timeline as graphical representation of a selection of NPIs, of relevance for this paper, implemented in Belgium. The figure is based on data and definitions from the European Centre for Disease Prevention and Control, to allow comparison with other countries (47). We compared the occurrence of viral respiratory pathogens in the period of April 2020 to April 2021 with three previous 12-month periods and report two major findings.

First, we observed a complete absence of IAV and IBV from March 2020 and January 2020 respectively, until the end of the study period. These findings are similar to those reported by another retrospective analysis of the Wuhan University Hospital, investigating the occurrence of influenza in children presenting between September and December from 2018 until 2020 (26). They reported a significantly lower positivity rate in 2020 (4.3%), compared to 2018 (14.0%) and 2019 (28.7%) (26). Likewise, an Italian tertiary hospital retrospectively compared the three winter seasons (September to February) from 2018 to 2021 (35). They did not detect any influenza virus in patients aged 0–18 years old during the last season, which contrasted with 2018-2019 (n = 240) and 2019-2020 (n = 354) (35). In that study, only five cases of RSV were detected in 2020-2021, compared to 2018-2019 (n = 726) and 2019-2020 (n = 689) (35). A Finnish study reported a shorter influenza and RSV season in early 2020 with a steeper decline from peak to zero cases than in the four previous years (8 vs. 13–20 weeks) (25). In the Southern Hemisphere as well, a significant reduction in detections of influenza (99.4%) and RSV (98.0%) was reported during the 2020 Australian winter compared to 2012-2019 (15). Our results are consistent with observations of the Belgian sentinel laboratories, reporting a reappearance of influenza virus only in December 2021 (48).

Second, we observed an absence of RSV from March 2020 onwards. Without its characteristic winter peak in November–December, RSV emerged in March 2021. The Belgian sentinel laboratories reported a more than 99% reduction in nationally detected cases of RV, ADV, and bocavirus in hospitalized children after implementation of NPIs against SARS-CoV-2, but its usual seasonality, has been described in literature as a global phenomenon (49–52).

Besides the two major findings discussed above, some additional results were of interest. We recognized a similar trend of PIV-3 in line with RSV, characterized by no cases from April 2020 to January 2021 and delayed emergence in February 2021. The annual positivity rate in 2020-2021, which at first sight might seem in conflict with an effect of NPIs, is solely attributed to the eleven positive tests which were detected in the last 2.5 months of the 2020-2021 period. Without differentiation between serotypes, the Belgian sentinel laboratories observed a decrease in occurrence of PIV starting March 2020 (48). In their report, the weekly number of positive cases remained low until a resurgence started in January 2021, peaking in March 2021 (48). The other respiratory viruses investigated in this study showed no statistically significant differences in occurrence in 2020-2021, compared to the three previous periods. ADV circulated throughout the year, in accordance with observations of the Belgian sentinel laboratories (48). The degree of impact from NPIs on viral epidemiology might in part be attributed to differences in structural pathogen characteristics, such as the presence (enveloped viruses) or absence (non-enveloped viruses) of a lipid envelope (53). Notably, enveloped viruses (such as influenza viruses, RSV, PIV, and coronavirus) are vulnerable to inactivation by alcohol-containing hand sanitizers and disinfectants (53). In contrast, non-enveloped viruses (such as human RV, ADV, and bocavirus) have relatively low sensitivity to alcohol-based inactivation (53). Comparing the timing of the implemented NPIs with our results, the absence of the affected respiratory viruses from March 2020 (RSV) and April 2020 (IAV, PIV-3) onwards can be associated with the first NPIs (including stay-at-home order, closure of schools and non-essential shops) being implemented as of March 2020. Subsequently, the resurgence of these viral pathogens starting February 2021 (PIV-3) and March 2021 (RSV) might be explained by the gradual relaxation of social measures (such as private and gatherings) as of early 2021.

In a hospital-based observational study from Taiwan, Chen et al. compared January-December 2019 to January-May 2020 and reported they did not observe epidemiological impact of NPIs on non-enveloped viruses (54). Instead, they noted an increase in HRV/ENT positivity rate in pediatric patients (54). A Canadian observational study compared the 2020-2021 season to five pre-pandemic respiratory virus seasons (2014–2019) and observed a dramatically lower incidence of seasonal respiratory viruses (including IAV, IBV, RSV, PIV, hMPV), except for ADV and HRV/ENT (27). The abovementioned Italian retrospective study reported a reduction in occurrence of RV in 2020-2021, albeit to a lesser extent than influenza viruses and RSV (35). Likewise, Kume et al. reported an overall decrease in detected cases of RV, ADV, and bocavirus in hospitalized children after implementation of NPIs against SARS-CoV-2, but
that these non-enveloped viruses were nonetheless consistently detected (55).

Strengths and limitations

We were able to gather an extensive dataset for this single-center retrospective study, from a large university hospital. As our dataset concerned young children presenting at this hospital, our results represent the local epidemiology. Although our results are in line with reports in literature, it is of relevance to analyze data on a regional scale. Especially since regional or international differences in degree and timing of NPIs might impede reliable comparison.

Nevertheless, we are aware that this dataset gives a biased view on the circulation of respiratory pathogens in the pediatric population. First, children with a milder clinical course of disease may not need medical attention and therefore, the causative agent will never be identified and documented. Second, compared to a multi-center analysis, a small difference in the data of this single hospital center might have a larger effect on the results. Third, one must acknowledge the subjective threshold for physicians of taking a respiratory sample in a child who does not require hospitalization. Since the cost of the analysis is often at the expense of the patient, physicians might be reluctant to systematically order a respiratory panel. Hence, the dataset concerned patients for whom it was expected to offer added diagnostic value. As mentioned above, the data concerned 453 respiratory panels of 411 unique patients. Based on this retrospective dataset, no consideration of underlying medical conditions of the included cases was possible. Lastly, the impact of the COVID-19 pandemic on the healthcare-seeking behavior of the population must not be taken lightly and might introduce bias. We are aware that differences in testing strategy and abovementioned remarks might influence the results. Consequently, we consider the results to be mainly explorative.

Future perspectives

The changes in epidemiology demonstrate that NPI can impact occurrence of viral respiratory infections in young children. A question remains to what extent NPIs such as face masks and lockdowns will be considered in managing any future epi- and pandemics, such as influenza (56, 57). Better understanding could lead to specific interventions to reduce the burden of these viral infections.

As social interaction in the absence of public health measures increases, healthcare providers should be wary of co-circulation of SARS-CoV-2 among other respiratory pathogens. The implications of co-infection with viruses and atypical bacteria on clinical features, laboratory and radiological examinations, treatments and outcomes are still unclear (58). Given that young children have the highest frequency of coinfections (notably with RSV and PIV or ADV), one must anticipate a future increment of coinfections with common respiratory viruses and SARS-CoV-2 (11, 59, 60).

Since this is a Belgian single-center analysis until April 2021, we provide a piece of the global picture of viral respiratory infection epidemiology during the COVID-19 pandemic. It is important to monitor this evolution through epidemiological surveillance, keeping in mind differences in local NPIs to allow reliable comparison and interpretation. Given the pandemic is still ongoing at the time of writing of this manuscript, we strongly encourage the repetition of this analysis in a few years, more in-depth and on a multi-center scale.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by Educational-Support Committee of the Research Ethics Committee UZ/KU Leuven. Written informed consent from the participants' legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.

Author contributions

DS: study conception, study design, data interpretation, and manuscript draft. AS: study conception, study design, data acquisition, data interpretation, and manuscript review. FV: study conception, data interpretation, and manuscript review. KL and AD: data interpretation and manuscript review. All authors have reviewed the final manuscript and have given approval for publishing.

Acknowledgments

This manuscript is based on a master's thesis at the Faculty of Medicine of KU Leuven, Belgium. This original thesis is included in the closed KU Leuven online library database (Limo, available only with login) (61). Special thanks to Tine Lewi, PhD, and Liesbeth Lewi, MD, PhD, for proofreading this manuscript and further suggestions concerning statistical analysis. The research activities of AS are supported by the Clinical Research and Education Council of the University Hospitals Leuven.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2022.931242/full#supplementary-material
